LESION VOLUME REDUCTION


First report of the DEFLECT-I MRI.
Interim results were presented at EuroPCR 2013 during the Hot-Line - First-in-man in Valvular Heart Disease session. 
Paris, France - May 22, 2013

Significant Lesion Volume Reduction 

Lesion Volume - Unprotected vs. DEFLECT-I with TriGuard


TriGuardâ„¢ - Making a Difference 

The First Report of the DEFLECT I Trial: 
A Prospective, Single Arm Feasibility Study to Evaluate the Safety and Performance of the KeyStone Heart TriGuardTM Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)

The presentation can be found below in PDF format.
 
First Report DEFLECT-I Study - EuroPCR 2013

The results were presented  at EuroPCR 2013 during the Hot-Line - First-in-man in Valvular Heart Disease session
by M.Mullen MD in Paris, France - May 22, 2013




The TriGuard Cerebral Protection Device is not yet commercially available in the USA.